Brief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
08/10/2026 14:09
BRIEF-Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements Oct 8 (Reuters) - Adc Therapeutics Ltd ADCT.N:
ADC THERAPEUTICS ANNOUNCES COMPREHENSIVE STRATEGIC FINANCIAL RESTRUCTURING MARKING KEY CAPITAL STRUCTURE IMPROVEMENTS
ADC THERAPEUTICS - SELLS 12.9 MILLION SHARES AT $1.42 AND 48.1 MILLION PRE-FUNDED WARRANTS AT $1.32
ADC THERAPEUTICS - PIPE GROSS PROCEEDS EXPECTED TO BE $86.60 MILLION BEFORE FEES
ADC THERAPEUTICS - EXPECTS Q3 NET PRODUCT REVENUES FROM ZYNLONTA SALES OF $21 MILLION
ADC THERAPEUTICS - AMENDED HEALTHCARE ROYALTY AGREEMENT REMOVING CHANGE-OF-CONTROL PAYMENT
ADC THERAPEUTICS - REFINANCED SENIOR SECURED LOAN, PRINCIPAL REDUCED TO $50 MILLION, BULLET PAYMENT AUGUST 2029
Source text: ID:nPn3mWq7Ga
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview